Table 1 Summary of adaptation of the FH KAP questionnaire
Item No | Original 19-Item FH KAP Questionnaire | Adapted 25-Item FH KAP Questionnaire |
|---|---|---|
Knowledge domain | ||
3 | Description of FH | Question rephrased |
4 | Lipid profile in FH | Answer rephrased |
6 | Prevalence of FH in Australia | Modified to prevalence of FH globally |
7 | Inheritance of FH | No change |
8 | CAD risk in FH | No change |
9 | Age threshold for premature CAD | Question rephrased |
11 | Genetic test in FH | No change |
22 | Â | Added: Target LDL-c in FH |
23 | Â | Added: Family history in FH |
24 | Â | Added: Exclusion of FH diagnosis |
25 | Â | Added: Management options in FH |
Total items: 7 | Â | Total items: 11 |
Awareness domain | ||
1 | Familiarity with FH | No change |
2 | Awareness of Australian FH guideline | Modified to awareness of NICE FH guideline |
16 | Awareness of lipid specialist service | No change except for question number |
19 | Â | Added: Awareness of FH diagnostic criteria |
20 | Â | Added: Awareness of other FH guidelines |
Total items: 3 | Â | Total items: 5 |
Practice domain | ||
5 | Assistance in FH detection | No change |
10 | Family screening of FH | Question rephrased |
12 | Number of FH patients under care | Moved to demography |
13 | Screening of relatives in FH | No change |
14 | Effective healthcare provider in FH | No change |
15 | Age for FH screening in young individuals | No change |
17 | Referral to lipid specialist | No change except for question number |
18 | Pharmacotherapy used in hypercholesterolaemia | Question rephrased |
19 | Combined pharmacotherapy used in severe hypercholesterolaemia | Question rephrased |
21 | Â | Added: CAD risk stratification in FH |
Total items: 9 | Â | Total items: 9 |